SummaryResearchers from the National Institutes of Health, the Chinese Academy of Sciences, and Wenzhou Medical University have recently co-developed a next-generation adenine base editor (ABE) with maximized editing accuracy and adequate editing efficiency in plant and human ...Learn More

Gene and cell therapy (GCT) is one of the fastest growing segments in the biopharmaceutical industry. Starting first with the approval and use for autologous CD54+ antigen presenting cells by the Food and Drug Administration (FDA), followed by several other allogeneic ...Learn More

Immuno-oncology, known as Cancer immunotherapy, is a type of biotherapy that uses components from live organisms to treat cancer. It is also known as biologic therapy or biological response modifier (BRM) therapy. It's a cancer treatment that harnesses the body's immune system's ...Learn More

Dr. Zuris discussed the rationale and approach for generating a new AsCas12a variant or AsCas12 ULTRA, how the newly developed variant compares in activity and specificity against other nucleases, and its application to T and NK cell gene editing.

When it comes to fighting cancer, the most important battle happens in the immune system – and leading this fight are T cells, the soldiers of the immune system. CAR T cell therapy is one way City of Hope scientists are empowering a patient’s own immune system to fight cancer. ...Learn More